# GTX Regimen for Biliary Cancers

> **NCT00868998** · PHASE2 · TERMINATED · sponsor: **Columbia University** · enrollment: 4 (actual)

## Conditions studied

- Biliary Cancer

## Interventions

- **DRUG:** Gemcitabine, docetaxel, and capecitabine

## Key facts

- **NCT ID:** NCT00868998
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2010-09
- **Final completion:** 2010-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Poor patient accrual
- **Last updated:** 2016-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868998, "GTX Regimen for Biliary Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00868998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*